Core Insights - Akebia Therapeutics, Inc. will present clinical data on Vadadustat at the 62nd European Renal Association Congress from June 4-7, 2025, in Vienna, both virtually and live [1] Company Overview - Akebia Therapeutics is a biopharmaceutical company founded in 2007, headquartered in Cambridge, Massachusetts, focused on improving the lives of individuals affected by kidney disease [2] - The company is fully integrated and aims to address the needs of patients with chronic kidney disease (CKD) [2] Presentation Highlights - Dr. Glenn Chertow will present a win-ratio analysis of the cardiovascular safety of Vadadustat in patients with CKD-related anemia undergoing dialysis on June 6 at 8:15 am CEST [2] - An e-poster will discuss the combination of Vadadustat with Ferric Citrate, highlighting its protective effects against inflammation-induced anemia and anemia caused by chronic kidney disease [2] - Insights from a Japanese database study on the real-world use of HIF-PH inhibitors and erythropoiesis-stimulating agents (ESAs) in non-dialysis-dependent CKD with anemia will also be presented [2]

Company Overview - Akebia Therapeutics, Inc. is a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease, founded in 2007 and headquartered in Cambridge, Massachusetts [3]. Upcoming Event - Akebia will present data at the National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25) in Boston, MA from April 10-13, 2025 [1]. - The company will have posters displayed during the Exhibit Hall hours at NKF SCM25 [1]. Research Presentation - On April 10, 2025, Dr. Wolfgang Winkelmayer will present a poster titled "Vadadustat for Treatment of Anemia in Older vs Younger Patients With Dialysis-Dependent-CKD" during the Oral Poster Presentation: Research 3 session [2]. - Akebia will also have a booth (1121) at the NKF SCM25 for attendees to visit [2].